Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 24, 2008. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 50,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,101.45 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.11% of total voting rights).
- Shares in Issue: 5,204,227,162 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding shares through the cancellation of the 50,000 shares purchased on November 24, 2008. This transaction increased the proportion of Treasury shares held by the Company to 9.11% of total voting rights.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (5,204,227,162) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the Treasury share count (474,194,158) and its impact on total voting rights (9.11%).
- Note that the 50,000 shares purchased were cancelled immediately upon acquisition.